Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Equity Income (2020 - 2024)

Sutro Biopharma's Equity Income history spans 5 years, with the latest figure at -$8.5 million for Q4 2024.

  • For Q4 2024, Equity Income fell 207.51% year-over-year to -$8.5 million; the TTM value through Jun 2025 reached -$8.5 million, down 149.7%, while the annual FY2023 figure was $9.9 million, 18.24% down from the prior year.
  • Equity Income for Q4 2024 was -$8.5 million at Sutro Biopharma, down from $4.8 million in the prior quarter.
  • Across five years, Equity Income topped out at $48.9 million in Q2 2020 and bottomed at -$37.1 million in Q4 2020.
  • The 5-year median for Equity Income is $3.6 million (2022), against an average of $3.3 million.
  • The largest annual shift saw Equity Income soared 558.88% in 2022 before it tumbled 1341.92% in 2023.
  • A 5-year view of Equity Income shows it stood at -$37.1 million in 2020, then surged by 93.07% to -$2.6 million in 2021, then skyrocketed by 558.88% to $11.8 million in 2022, then tumbled by 33.14% to $7.9 million in 2023, then plummeted by 207.51% to -$8.5 million in 2024.
  • Per Business Quant, the three most recent readings for STRO's Equity Income are -$8.5 million (Q4 2024), $4.8 million (Q2 2024), and $3.7 million (Q1 2024).